{
    "nct_id": "NCT03131999",
    "official_title": "LAM Pilot Study With Imatinib Mesylate",
    "inclusion_criteria": "* Definite or Probable LAM\n* FVC or Postbronchodilator FEV1 <90% predicted\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or planned pregnancy or lactation\n* Unwillingness to discontinue sirolimus\n* Change in the dose or use of sirolimus within the past month\n* Inability to perform spirometry\n* Allergy or intolerance of albuterol and/or ipratropium\n* Other serious illness that would impact the outcome of the study including cancer that has not received curative therapy, Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study), uncontrolled diabetes, chronic renal disease, chronic liver disease, or active uncontrolled infection\n* Current lung transplant\n* Known diagnosis of human immunodeficiency virus (HIV) infection\n* Current cigarette smoking\n* Required use of warfarin, ketoconazole, itraconazole, clarithromycin, or rifampin during the 2 months of the study.\n* Unwillingness to avoid grapefruit juice or St. Johns Wort during the study.\n* Planned surgery during the 2 months of the study.\n* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.\n* Patient has received and other investigational agents within 28 days of first day of study drug dosing.",
    "miscellaneous_criteria": ""
}